Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1969 1
1971 1
1976 1
1978 1
1979 2
1980 2
1982 1
1983 3
1984 1
1986 3
1987 2
1989 3
1990 6
1991 1
1992 1
1993 2
1994 4
1995 3
1996 2
1997 5
1998 3
1999 7
2000 4
2001 3
2002 2
2003 10
2004 8
2005 10
2006 10
2007 7
2008 8
2009 13
2010 7
2011 12
2012 10
2013 15
2014 20
2015 19
2016 23
2017 29
2018 18
2019 23
2020 22
2021 16
2022 15
2023 16
2024 11

Text availability

Article attribute

Article type

Publication date

Search Results

333 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Intellectual developmental disorder 61"
Page 1
Association of Antipsychotic Drug Exposure in Pregnancy With Risk of Neurodevelopmental Disorders: A National Birth Cohort Study.
Straub L, Hernández-Díaz S, Bateman BT, Wisner KL, Gray KJ, Pennell PB, Lester B, McDougle CJ, Suarez EA, Zhu Y, Zakoul H, Mogun H, Huybrechts KF. Straub L, et al. JAMA Intern Med. 2022 May 1;182(5):522-533. doi: 10.1001/jamainternmed.2022.0375. JAMA Intern Med. 2022. PMID: 35343998 Free PMC article.
EXPOSURES: At least 1 dispensing of a medication during the second half of pregnancy (period of synaptogenesis), assessed for any antipsychotic drug, at the class level (atypical and typical), and for the most commonly used drugs (aripiprazole, olanzapine, quetiapine, risperidone …
EXPOSURES: At least 1 dispensing of a medication during the second half of pregnancy (period of synaptogenesis), assessed for any antipsycho …
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ, Storm MRO, Pereira Ribeiro J, Skoog M, Groth C, Callesen HE, Schaug JP, Darling Rasmussen P, Huus CL, Zwi M, Kirubakaran R, Simonsen E, Gluud C. Storebø OJ, et al. Cochrane Database Syst Rev. 2023 Mar 27;3(3):CD009885. doi: 10.1002/14651858.CD009885.pub3. Cochrane Database Syst Rev. 2023. PMID: 36971690 Free PMC article. Review.
The search was not limited by publication year or language, but trial inclusion required that 75% or more of participants had a normal intellectual quotient (IQ > 70). ...MAIN RESULTS: We included 212 trials (16,302 participants randomised); 55 parallel-gr …
The search was not limited by publication year or language, but trial inclusion required that 75% or more of participants had a norma …
Long-term medication for ADHD and development of cognitive functions in children and adolescents.
Johnson M, Åsberg Johnels J, Östlund S, Cedergren K, Omanovic Z, Hjalmarsson K, Jakobsson K, Högstedt J, Billstedt E. Johnson M, et al. J Psychiatr Res. 2021 Oct;142:204-209. doi: 10.1016/j.jpsychires.2021.07.055. Epub 2021 Aug 2. J Psychiatr Res. 2021. PMID: 34375772 Free article. Clinical Trial.
STUDY DESIGN: This study is part of an ongoing open uncontrolled trial of long-term medication for ADHD in children and adolescents aged 6-18 years with any form of ADHD, and frequently comorbid autism spectrum disorder (ASD, 29%) or autistic traits (24%). Other com …
STUDY DESIGN: This study is part of an ongoing open uncontrolled trial of long-term medication for ADHD in children and adolescents a …
Methylphenidate for children and adolescents with attention deficit hyperactivity disorder (ADHD).
Storebø OJ, Ramstad E, Krogh HB, Nilausen TD, Skoog M, Holmskov M, Rosendal S, Groth C, Magnusson FL, Moreira-Maia CR, Gillies D, Buch Rasmussen K, Gauci D, Zwi M, Kirubakaran R, Forsbøl B, Simonsen E, Gluud C. Storebø OJ, et al. Cochrane Database Syst Rev. 2015 Nov 25;2015(11):CD009885. doi: 10.1002/14651858.CD009885.pub2. Cochrane Database Syst Rev. 2015. PMID: 26599576 Free PMC article. Updated. Review.
At least 75% of participants needed to have an intellectual quotient of at least 70 (i.e. normal intellectual functioning). ...MAIN RESULTS: The studies.We included 38 parallel-group trials (5111 participants randomised) and 147 cross-over trials (7134 partic …
At least 75% of participants needed to have an intellectual quotient of at least 70 (i.e. normal intellectual functioning). .. …
Acetylcholinesterase inhibitors for autistic spectrum disorders.
Ure A, Cox GR, Haslam R, Williams K. Ure A, et al. Cochrane Database Syst Rev. 2023 Jun 1;6(6):CD013851. doi: 10.1002/14651858.CD013851.pub2. Cochrane Database Syst Rev. 2023. PMID: 37267443 Review.
BACKGROUND: Autism spectrum disorder (autism) is a neurodevelopmental condition characterised by impairments in social communication and interaction, plus restricted, repetitive patterns of behaviour and interests. ...People of any age, with a clinical diagnosis of …
BACKGROUND: Autism spectrum disorder (autism) is a neurodevelopmental condition characterised by impairments in social communication …
The clinical and molecular spectrum of ZFYVE26-associated hereditary spastic paraplegia: SPG15.
Saffari A, Kellner M, Jordan C, Rosengarten H, Mo A, Zhang B, Strelko O, Neuser S, Davis MY, Yoshikura N, Futamura N, Takeuchi T, Nabatame S, Ishiura H, Tsuji S, Aldeen HS, Cali E, Rocca C, Houlden H, Efthymiou S, Assmann B, Yoon G, Trombetta BA, Kivisäkk P, Eichler F, Nan H, Takiyama Y, Tessa A, Santorelli FM, Sahin M, Blackstone C, Yang E, Schüle R, Ebrahimi-Fakhari D. Saffari A, et al. Brain. 2023 May 2;146(5):2003-2015. doi: 10.1093/brain/awac391. Brain. 2023. PMID: 36315648 Free PMC article.
We demonstrate that most patients present with motor and/or speech delay or learning disabilities. Importantly, these developmental symptoms preceded the onset of motor symptoms by several years. ...These results raise awareness to this rare disease, facilitate an early di …
We demonstrate that most patients present with motor and/or speech delay or learning disabilities. Importantly, these developmental s …
Efficacy and tolerability of brivaracetam in patients with intellectual disability and epilepsy.
Gillis RME, Wammes-van der Heijden EA, Schelhaas HJ, Tan IY, Festen DAM, Majoie MHJM. Gillis RME, et al. Acta Neurol Belg. 2021 Jun;121(3):677-684. doi: 10.1007/s13760-020-01324-3. Epub 2020 Mar 10. Acta Neurol Belg. 2021. PMID: 32157673
Patients with intellectual disability (ID) are often excluded from clinical trials, and little is known about the best approach to treat their epilepsy. ...
Patients with intellectual disability (ID) are often excluded from clinical trials, and little is known about the best …
Effects of multiple-dose intranasal oxytocin administration on social responsiveness in children with autism: a randomized, placebo-controlled trial.
Daniels N, Moerkerke M, Steyaert J, Bamps A, Debbaut E, Prinsen J, Tang T, Van der Donck S, Boets B, Alaerts K. Daniels N, et al. Mol Autism. 2023 Apr 20;14(1):16. doi: 10.1186/s13229-023-00546-5. Mol Autism. 2023. PMID: 37081454 Free PMC article. Clinical Trial.
BACKGROUND: Intranasal administration of oxytocin is increasingly explored as a new approach to facilitate social development and reduce disability associated with a diagnosis of autism spectrum disorder (ASD). ...Trial registration The trial was regis …
BACKGROUND: Intranasal administration of oxytocin is increasingly explored as a new approach to facilitate social development and reduce …
Mental, Neurological, and Somatic Comorbidities and Their Treatment in Persons With Intellectual Disability.
Weih M, Köhler S, Schöll N, Schulz M, Hering R. Weih M, et al. Dtsch Arztebl Int. 2022 Jun 17;119(24):418-414. doi: 10.3238/arztebl.m2022.0193. Dtsch Arztebl Int. 2022. PMID: 35506265 Free PMC article.
BACKGROUND: Persons with intellectual disability (ID) often suffer from significant comorbidities. ...Future analyses should be devoted to the specific care of people with intellectual disability, who constitute an especially multimorbid and vulnerable …
BACKGROUND: Persons with intellectual disability (ID) often suffer from significant comorbidities. ...Future analyses should b …
Efficacy and safety of balovaptan for socialisation and communication difficulties in autistic adults in North America and Europe: a phase 3, randomised, placebo-controlled trial.
Jacob S, Veenstra-VanderWeele J, Murphy D, McCracken J, Smith J, Sanders K, Meyenberg C, Wiese T, Deol-Bhullar G, Wandel C, Ashford E, Anagnostou E. Jacob S, et al. Lancet Psychiatry. 2022 Mar;9(3):199-210. doi: 10.1016/S2215-0366(21)00429-6. Epub 2022 Feb 10. Lancet Psychiatry. 2022. PMID: 35151410 Clinical Trial.
METHODS: V1aduct was a phase 3, randomised, placebo-controlled, double-blind trial, conducted at 46 sites across six countries (the USA, the UK, France, Italy, Spain, and Canada). Eligible participants were aged 18 years or older with an intelligence quotient (IQ) o …
METHODS: V1aduct was a phase 3, randomised, placebo-controlled, double-blind trial, conducted at 46 sites across six countries …
333 results